Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Values were normalized to the protein concentration of each cell line (left)
Phase 2 results published in The Lancet (2023) demonstrated dose-dependent body weight reductions of up to approximately 16.9% and meaningful HbA1c improvements at 24 weeks in adults with type 2 diabetes
Always consult a qualified clinician before starting any treatment
References PubChem search: Melanotan I afamelanotide PubMed: Melanotan I afamelanotide alpha-MSH PubMed: MC1R melanocortin peptide analogue Research-use notice: Supplied strictly for lawful research, laboratory, analytical, educational, or R&D purposes where permitted by applicable law
US$ 22.49
US$ 26.87
US$ 26.74
US$ 24.66
US$ 28.94
US$ 28.01
